Prostate Cancer Clinical Trials in Maryland

Showing 41-60 of 439 trials

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT05283330

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors

Cervical CancerBreast CancerColon Cancer+4 more

Orano Med LLC48 participantsStarted Dec 2022

Chicago, Illinois, United States • Lexington, Kentucky, United States • Glen Burnie, Maryland, United States +1 more locations

COMPLETEDPhase 312 miles

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

NCT00936390

RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.

Prostate Cancer

Radiation Therapy Oncology Group1,538 participantsStarted Sep 2009

Birmingham, Alabama, United States • Fairbanks, Alaska, United States • Peoria, Arizona, United States +515 more locations

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Prostate Cancer Trials in Other Cities

A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.

Other Conditions in Maryland